Production and Application of CAR T Cells: Current and Future Role of Europe
Rapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is play...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.713401/full |
| _version_ | 1818915105585233920 |
|---|---|
| author | Vladan Vucinic Andrea Quaiser Philipp Lückemeier Stephan Fricke Stephan Fricke Uwe Platzbecker Ulrike Koehl Ulrike Koehl Ulrike Koehl |
| author_facet | Vladan Vucinic Andrea Quaiser Philipp Lückemeier Stephan Fricke Stephan Fricke Uwe Platzbecker Ulrike Koehl Ulrike Koehl Ulrike Koehl |
| author_sort | Vladan Vucinic |
| collection | DOAJ |
| description | Rapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is playing. On the other hand, an overview of reproducible processing techniques is presented, from manual or semi-automated up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory requirements, an outlook is given in the direction of digitally controlled automated manufacturing in order to lower cost and complexity and to address CAR T cell products for a greater number of patients and a variety of malignant diseases. |
| first_indexed | 2024-12-19T23:56:59Z |
| format | Article |
| id | doaj.art-0d1f028838e44f21bb422bf9fd22cac7 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-19T23:56:59Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-0d1f028838e44f21bb422bf9fd22cac72022-12-21T20:00:59ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.713401713401Production and Application of CAR T Cells: Current and Future Role of EuropeVladan Vucinic0Andrea Quaiser1Philipp Lückemeier2Stephan Fricke3Stephan Fricke4Uwe Platzbecker5Ulrike Koehl6Ulrike Koehl7Ulrike Koehl8University of Leipzig, Medical Clinic for Hematology, Cell Therapy and Hemostaseology, Leipzig Medical Center, Leipzig, GermanyFraunhofer Institute for Cell Therapy and Immunology, Leipzig, GermanyUniversity of Leipzig, Medical Clinic for Hematology, Cell Therapy and Hemostaseology, Leipzig Medical Center, Leipzig, GermanyFraunhofer Institute for Cell Therapy and Immunology, Leipzig, GermanyDepartment of Internal Medicine III Hematology, Oncology, Stem Cell Transplantation, Klinikum Chemnitz gGmbH, Chemnitz, GermanyUniversity of Leipzig, Medical Clinic for Hematology, Cell Therapy and Hemostaseology, Leipzig Medical Center, Leipzig, GermanyFraunhofer Institute for Cell Therapy and Immunology, Leipzig, GermanyInstitute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, GermanyInstitute for Cellular Therapeutics, Hannover Medical School, Hannover, GermanyRapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is playing. On the other hand, an overview of reproducible processing techniques is presented, from manual or semi-automated up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory requirements, an outlook is given in the direction of digitally controlled automated manufacturing in order to lower cost and complexity and to address CAR T cell products for a greater number of patients and a variety of malignant diseases.https://www.frontiersin.org/articles/10.3389/fmed.2021.713401/fullCAR T cellscancer treatmentmanufacturingautomationregulation |
| spellingShingle | Vladan Vucinic Andrea Quaiser Philipp Lückemeier Stephan Fricke Stephan Fricke Uwe Platzbecker Ulrike Koehl Ulrike Koehl Ulrike Koehl Production and Application of CAR T Cells: Current and Future Role of Europe Frontiers in Medicine CAR T cells cancer treatment manufacturing automation regulation |
| title | Production and Application of CAR T Cells: Current and Future Role of Europe |
| title_full | Production and Application of CAR T Cells: Current and Future Role of Europe |
| title_fullStr | Production and Application of CAR T Cells: Current and Future Role of Europe |
| title_full_unstemmed | Production and Application of CAR T Cells: Current and Future Role of Europe |
| title_short | Production and Application of CAR T Cells: Current and Future Role of Europe |
| title_sort | production and application of car t cells current and future role of europe |
| topic | CAR T cells cancer treatment manufacturing automation regulation |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.713401/full |
| work_keys_str_mv | AT vladanvucinic productionandapplicationofcartcellscurrentandfutureroleofeurope AT andreaquaiser productionandapplicationofcartcellscurrentandfutureroleofeurope AT philippluckemeier productionandapplicationofcartcellscurrentandfutureroleofeurope AT stephanfricke productionandapplicationofcartcellscurrentandfutureroleofeurope AT stephanfricke productionandapplicationofcartcellscurrentandfutureroleofeurope AT uweplatzbecker productionandapplicationofcartcellscurrentandfutureroleofeurope AT ulrikekoehl productionandapplicationofcartcellscurrentandfutureroleofeurope AT ulrikekoehl productionandapplicationofcartcellscurrentandfutureroleofeurope AT ulrikekoehl productionandapplicationofcartcellscurrentandfutureroleofeurope |